Clinical trial
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
NCT00128271 · Peregrine Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00128271 |
|---|---|
| Title | Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection |
| Official title | A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin |
| Lead sponsor | Peregrine Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Bavituximab |
| Enrollment | 32 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2006 |
| First posted | Aug 9, 2005 |
| Last update posted | May 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: